STAFF BOARD
Article
CHAIRMAN
Virginia Hernández Corredoira
EDITOR IN CHIEF
Manuela Velázquez Prieto
Jaime E. Poquet Jornet
MARKETING MANAGER
EDITORIAL BOARD
Ramón Jódar Masanés
Lluís Campins Bernadas
Tomás Casasín Edo
Juan Carlos Juárez Giménez
Carles Quiñones Ribas
Volume 22 - Issue 2, April-June 2020
REVIEWS
IMMUNOTHERAPY FOR NON-SMALL CELL LUNG CANCER
RAMÓN ALBERT ANTONIO


Lung cancer (LC) is one of the most common malignancies, and non-small cell lung cancer (NSCLC) represents almost 85% of diagnosed cases of LC. For pa- tients with resectable early-stage NSCLC, surgery is the best therapeutic option when possible, and adjuvant chemotherapy provides an additional benefit.
At present, treatment options for patients with advanced disease include: chemotherapy, targeted
therapies, and immunotherapy; In specific cases, local treatment with radiotherapy or surgery is
recommended to palliate the symptoms. To stipulate the treatment, it is essential to know besides
the histological charac- teristics, the molecular and immunological characteristics of the tumor,
evaluat- ing the genomic changes of the tumor and the PD-L1 expression. Immunotherapy alone and
combined with chemotherapy has achieved superior benefits than for- mer standard treatments.
In this non-systematic review, the outcomes of the latest trials regarding the use of immunotherapy
in different conntttexts are discussed. Parallely, finding pre- dictive response biomarkers
anndd/oorr ccrriiteria for aan early response assessment is challenging.

ANTI-PD-1 – ANTI-PD-L1 – IMMUNE CHECKPOINT INHIBITORS – IMMUNOTHERAPY – NSCLC



Fill out the form below to buy this article

Name and surname:

DNI/NIF ID/VAT IDENTIFICATION No.:

Contact Email:

Phone:

Address:

Zip code:

City:

Province:

Country:

*I have read and accept the privacy policy
Price : 30,25